TezNewz teznewz

Real-time AI-scored market movers with ± impact ratings from -100 to +100. Latest: UBS Maintains Sell on National Beverage, Lowers Price Target to $35 (Impact: -70). TezNewz delivers instant financial news analysis through Discord with sector-specific insights and comprehensive market intelligence.

Financial News with AI Impact Scores

Get real-time financial news with AI-powered impact analysis delivered through Discord

Today's Market Overview

TezNewz delivers AI-scored financial news with impact ratings from -100 to +100. Latest stories cover Unknown, Consumer Cyclical sectors. Top impact story: "UBS Maintains Sell on National Beverage, Lowers Price Target to $35" with -70 impact score. Join our Discord community for real-time alerts and discussions.

Latest News

Unknown -60 DOCU

Docusign Posts Q3 Beat; Outlook Reflects Revenue Deceleration

Docusign Inc (NASDAQ: DOCU) reported a third-quarter revenue of $818 million, reflecting an 8.4% year-on-year growth, and billings increased by 10.3% to $829 million. Despite these results beating consensus estimates, shares fell 6.23% to $66.67 due to concerns over revenue deceleration, with management guiding for fourth-quarter revenue of $827 million, indicating a slowdown to approximately 6.5% year-on-year growth. Analysts from JPMorgan and Needham maintained neutral ratings, with JPMorgan lowering its price target from $80 to $78.

Consumer Cyclical +80 ULTA

UBS Maintains Buy on Ulta Beauty, Raises Price Target to $690

UBS analyst Michael Lasser has reaffirmed a Buy rating on Ulta Beauty (NASDAQ: ULTA) and increased the price target from $680 to $690. This adjustment reflects a positive outlook for the company's performance in the market.

Healthcare +70 CNMD

Conmed Dumps Gastroenterology Business To Focus On Core Surgical Markets

CONMED Corporation announced its exit from the gastroenterology product lines to concentrate on higher-growth surgical markets, including minimally invasive and robotic surgery. This move is expected to impact earnings in the near term, with an anticipated EPS dilution of 45 to 55 cents in 2026, while improving the company's gross margin profile by approximately 80 basis points post-exit. The gastroenterology portfolio was projected to generate $90 million to $95 million in revenue for 2025. Following the announcement, CNMD shares fell by 9.43% to $40.07.